School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan.
Department of Neurosurgery, China Medical University Hospital, Taichung 40447, Taiwan.
Sci Rep. 2017 Mar 31;7:45628. doi: 10.1038/srep45628.
PG2 is an infusible polysaccharide extracted from Astragalus membranaceus, which is a Chinese herb traditionally used for stroke treatment. We investigated the effect of PG2 on patients with spontaneous acute intracerebral hemorrhage (ICH). A total of 61 patients with acute spontaneous ICH were randomized to either the treatment group (TG, 30 patients), which received 3 doses of PG2 (500 mg, IV) per week for 2 weeks, or the control group (CG, 31 patients), which received PG2 placebo. At 84 days after PG2 administration, the percentage of patients with a good Glasgow outcome scale (GOS 4-5) score in the TG was similar to that in the CG (69.0% vs. 48.4%; p = 0.2). The percentage of good mRS scores (0-2) in the TG was similar to that in the CG (62.1% vs. 45.2%; p = 0.3). In addition, no significant differences were seen when comparing differences in the C-reactive protein, erythrocyte sedimentation rate, interleukin-6 (IL-6), IL-1β, tumor necrosis factor-α, and S100B levels between baseline and days 4, 7, and 14 after PG2 administration (all p > 0.05). The results are preliminary, necessitating a more thorough assessment.
PG2 是一种从黄芪中提取的不可溶多糖，黄芪是一种传统上用于治疗中风的中药。我们研究了 PG2 对自发性急性脑出血（ICH）患者的影响。共有 61 名急性自发性 ICH 患者被随机分为治疗组（TG，30 名患者）和对照组（CG，31 名患者）。治疗组每周接受 3 次 PG2（500mg，静脉注射），共 2 周，对照组接受 PG2 安慰剂。PG2 给药后 84 天，TG 中格拉斯哥结局量表（GOS）评分良好（GOS 4-5）的患者比例与 CG 相似（69.0%比 48.4%；p=0.2）。TG 中良好 mRS 评分（0-2）的患者比例与 CG 相似（62.1%比 45.2%；p=0.3）。此外，与基线相比，PG2 给药后第 4、7 和 14 天，两组间 C 反应蛋白、红细胞沉降率、白细胞介素-6（IL-6）、白细胞介素-1β、肿瘤坏死因子-α和 S100B 水平的差异无统计学意义（均 p>0.05）。结果初步表明，还需要更全面的评估。
